During the past decade, Johns Hopkins University conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 14 clinical trials were completed, i.e. on average, 233.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Johns Hopkins University" #1 sponsor was "Gilead Sciences" with 11 trials, followed by "Bristol-Myers Squibb" with 10 trials sponsored, "Johns Hopkins Bloomberg School of Public Health" with 3 trials sponsored, "Johns Hopkins University" with 3 trials sponsored and "New River Pharmaceuticals" with 3 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Johns Hopkins University" #1 collaborator was "American Diabetes Association" with 2 trials as a collaborator, "Janssen Research & Development, LLC" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Johns Hopkins University" with 1 trials as a collaborator and "M.D. Anderson Cancer Center" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Johns Hopkins University" are "Chronic Hepatitis C" (7 trials), "Hepatitis C" (6 trials), "Hepatitis C, Chronic" (3 trials), "Acquired Immunodeficiency Syndrome" (2 trials) and "Attention Deficit Disorders With Hyperactivity" (2 trials). Many other conditions were trialed in "Johns Hopkins University" in a lesser frequency.

Most popular intervention types in "Johns Hopkins University" are "Drug" (25 trials), "Behavioral" (4 trials), "Biological" (2 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ribavirin" (8 trials), "Daclatasvir" (6 trials), "RBV" (4 trials), "SOF" (3 trials) and "Sofosbuvir" (3 trials). Other intervention names were less common.

The vast majority of trials in "Johns Hopkins University" are 32 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Johns Hopkins University". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Johns Hopkins University, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Johns Hopkins University, 0 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".